5.9 | | Srrm3 | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
5.2 | | Srrm3 | 'neurogenin-3-expressing endocrine progenitor cell' vs 'neurogenin-3-lacking pancreatic progenitor cell' at 'embryonic day 15.5' | cell type, developmental stage | Transcription profiling by high throughput sequencing of murine beta cells at key stages of maturation |
3.5 | | Srrm3 | 'Insm1-expressing endocrine progenitor cell' vs 'Insm1-lacking endocrine progenitor cell' in 'embryonic day 15.5' | cell type, developmental stage | Transcriptional regulation of endocrine cell differentiation by Insm1 |
3.5 | | Srrm3 | 'Ngn3-expressing cell' vs 'Ngn3-null cell' | cell type | Transcriptional profiling of Ngn3-dependent pancreatic endocrine differentiation at E15.5 |
-3.3 | | Srrm3 | 'extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
3.2 | | Srrm3 | 'etoposide; 2.5 micromolar' vs 'none' in 'wild type genotype' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
2.8 | | Srrm3 | 'SARS coronavirus MA15; 2 day' vs 'mock' in 'CAST/EiJ' | infect, strain, time | Genomic profiling of collaborative cross founder mouse strains infected with respiratory viruses to discover novel transcripts and infection-related strain-specific gene and isoform expression |
2.7 | | Srrm3 | 'neuron' vs 'differentiating progenitor' | cell type | Transcription profiling by high throughput sequencing of proliferating neural stem cells, differentiating neurogenic progenitors and newborn neurons using a dual-reporter mouse line |
-2.7 | | Srrm3 | 'proliferating progenitor' vs 'differentiating progenitor' | cell type | Transcription profiling by high throughput sequencing of proliferating neural stem cells, differentiating neurogenic progenitors and newborn neurons using a dual-reporter mouse line |
2.7 | | Srrm3 | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
-2.4 | | Srrm3 | 'XBP1s overexpression' vs 'wild type genotype' in '4μ8C; 15 micromolar' | compound, genotype | Overexpression of spliced XBP1 in in vitro Th2 cells, and comparison to 4u8c treatment |
2.3 | | Srrm3 | 'neurosphere in differentiation medium; 5 day' vs 'neurosphere; 0 day' in 'wild type genotype' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
2.2 | | Srrm3 | 'etoposide; 2.5 micromolar' vs 'none' in 'H2afj-∆7-KO' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
2.2 | | Srrm3 | 'colitis' at '8 day' vs 'normal' at '0 day' | disease, time | Temporal transcriptomic changes during DSS colitis development and resolution. |
-2.2 | | Srrm3 | 'H-Ras expression' vs 'wild type' | phenotype | RNA-seq of heart tissue from 15 day old mice 4 hours post MycER activation compared to wild type controls. RNA-seq of heart tissues from adult mice that have expressed oncogenic H-Ras for 4 weeks followed by MycER activation for 4 hours compared to MycER negative controls. |
1.9 | | Srrm3 | 'SOD1-G93A transgenic' vs 'wild type' at 'day 65' in 'B6/SJL' | genotype, sampling time point, strain | Transcription profiling by high throughput sequencing of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model |
1.7 | | Srrm3 | 'Er1F/-' vs 'wild type genotype' | genotype | RNA-Seq profiling of ERCC1-XPF DNA repair defect (Er1F/-) versus wild type (Er1F/+) macrophages |
1.7 | | Srrm3 | 'Pdx1::Ngn3ER' vs 'Ngn3 knock out' | genotype | Transcriptome profiling of mouse pancreatic epithelium from Pdx1-Ngn3ER-IRES-GFP mice bred into a Neurog3-null background at embryonic day 11.25 |
-1.6 | | Srrm3 | 'pabpn1l -/-' vs 'wild type genotype' in 'zygote' | genotype, organism part | RNA-seq of oocytes and zygotes from pabpn1l ko and wt female mice |
-1.6 | | Srrm3 | 'adenoviral vector expressing human ACE2' vs 'empty adenoviral vector' | genotype | RNA-seq of SARS-CoV-2 infected lungs from mice sensitized for SARS-CoV-2 infection by Ad5-hACE2 transduction compared to non-sensitized mice |
1.5 | | Srrm3 | 'PS2APP transgenic' vs 'non transgenic' in 'astrocyte' at '13 month' | age, cell type, genotype | Transcription profiling by high throughput sequencing of astrocytes, microglial and neuronal cells from an Alzheimer's mouse model |
1.4 | | Srrm3 | 'neurosphere in differentiation medium; 5 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.3 | | Srrm3 | 'transgenic' vs 'wild type' in '160 day; C57BL/6' | age, genotype, strain | Whole genome transcriptome analysis identifies indices of fast and slow disease progression in two ALS mouse models |
1.2 | | Srrm3 | 'neurosphere in differentiation medium; 12 day' vs 'neurosphere; 0 day' in 'Cstb knockout' | genotype, growth condition, time | Transcriptome analysis of neurospheres derived from Cstb-KO mouse embryo brains during differentiation |
-1.1 | | Srrm3 | 'SARS coronavirus MA15 dORF6' vs 'none' at '2 day' | infect, time | SM012 - SARS MA15 wild type, and SARS deltaORF6 mutant virus infections of C57BL6 mice - A time course |
1 | | Srrm3 | 'R6/2 transgenic' vs 'wild type' in '8 week; brain cortex' | age, genotype, organism part | Transcription profiling by high throughput sequencing in wild type and R6/2 mutant mouse cortex and striatum at 8 and 12 weeks. |
-1 | | Srrm3 | 'CXCR3 knockout; SARS MA15; 2 day' vs 'CXCR3 knockout; mock' | genotype, infect, time | Infection of wild type and CXCR3 knockout C57BL6/J mice with SARS MA15 |